FDA advisory committee debates safety and efficacy standards for a coronavirus vaccine

The panel did not consider any specific vaccine, and the session served in large part as a venue for the agency to try to reassure the general public that any vaccine will be held to a high standard.

View original article
Contributor: Laurie McGinley